Casdin Capital 13F holdings, Q1 2021
Holdings as of March 31, 2021 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 48 US equity positions worth $3.4bn in its Q1 2021 13F filing. The largest position was INVITAE CORP at 13.9% of the reported book, followed by EXK and FATE. Against the Q4 2020 filing, it opened 4 new positions, added to 15 and reduced 6 among the top 48 holdings.
What did Casdin Capital own in Q1 2021? Top 48 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2020 |
|---|---|---|---|---|---|---|---|
| 1 | INVITAE CORP | 13.9% | $466.3m | 12,203,669 | -1% | reduced | |
| 2 | EXK EXACT SCIENCES CORP | Basic Materials | 9.3% | $311.0m | 2,360,186 | 59% | added |
| 3 | FATE FATE THERAPEUTICS INC | Healthcare | 8.3% | $280.3m | 3,400,000 | 11% | added |
| 4 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 8.0% | $267.8m | 7,440,107 | 0% | held |
| 5 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 5.0% | $166.6m | 5,000,000 | 0% | held |
| 6 | 2655787D BLUEPRINT MEDICINES CORP | 4.5% | $150.7m | 1,550,000 | 0% | held | |
| 7 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.7% | $124.2m | 880,000 | 13% | added |
| 8 | TWST TWIST BIOSCIENCE CORP | Healthcare | 3.7% | $123.9m | 1,000,000 | 0% | held |
| 9 | RLAY RELAY THERAPEUTICS INC | Healthcare | 3.5% | $116.7m | 3,375,058 | -11% | reduced |
| 10 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.3% | $111.8m | 2,165,000 | -9% | reduced |
| 11 | CDXS CODEXIS INC | Healthcare | 3.0% | $99.1m | 4,330,000 | 0% | held |
| 12 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.7% | $91.9m | 1,610,000 | 23% | added |
| 13 | DERMTECH INC | 2.6% | $88.6m | 1,745,000 | 27% | added | |
| 14 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.5% | $84.6m | 1,844,535 | 13% | added |
| 15 | CDNA CAREDX INC | Healthcare | 2.4% | $81.3m | 1,193,335 | 0% | held |
| 16 | BEAM BEAM THERAPEUTICS INC | Healthcare | 2.0% | $65.5m | 818,820 | 78% | added |
| 17 | ONC BEIGENE LTD | Healthcare | 1.6% | $52.2m | 150,000 | 0% | held |
| 18 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.4% | $46.3m | 1,150,000 | 61% | added |
| 19 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.4% | $45.9m | 1,300,000 | 38% | added |
| 20 | GENERATION BIO CO | 1.4% | $45.9m | 1,611,214 | 0% | held | |
| 21 | 4D MOLECULAR THERAPEUTICS IN | 1.3% | $43.2m | 995,354 | 28% | added | |
| 22 | CNST CONSTELLATION PHARMCETICLS I | 1.3% | $42.1m | 1,800,000 | 1% | added | |
| 23 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.2% | $41.0m | 550,000 | 4% | added |
| 24 | MAGENTA THERAPEUTICS INC | 1.2% | $39.6m | 3,346,034 | 0% | held | |
| 25 | GLOBAL BLOOD THERAPEUTICS IN | 1.1% | $36.7m | 900,000 | 11% | added | |
| 26 | ALEC ALECTOR INC | Healthcare | 1.0% | $33.2m | 1,650,000 | 0% | held |
| 27 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.0% | $32.5m | 266,430 | 0% | held |
| 28 | ZLAB ZAI LAB LTD | Healthcare | 0.8% | $25.4m | 190,000 | 0% | held |
| 29 | ORCHARD THERAPEUTICS PLC | 0.7% | $23.3m | 3,215,434 | – | new | |
| 30 | BNR BURNING ROCK BIOTECH LTD | 0.7% | $22.8m | 847,150 | -56% | reduced | |
| 31 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.7% | $22.4m | 1,000,000 | 122% | added |
| 32 | ADVERUM BIOTECHNOLOGIES INC | 0.6% | $21.8m | 2,211,622 | -39% | reduced | |
| 33 | MASS 908 DEVICES INC | 0.6% | $19.7m | 406,502 | 0% | held | |
| 34 | KRONOS BIO INC | 0.5% | $17.1m | 583,436 | 0% | held | |
| 35 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.5% | $16.7m | 820,440 | 0% | held |
| 36 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.4% | $14.7m | 601,515 | 0% | held |
| 37 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.4% | $14.6m | 1,241,176 | 0% | held |
| 38 | DECIBEL THERAPEUTICS INC | 0.4% | $13.0m | 1,146,421 | – | new | |
| 39 | BERKELEY LTS INC | 0.3% | $10.0m | 200,000 | 0% | held | |
| 40 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.3% | $9.5m | 610,000 | 65% | added |
| 41 | SEER SEER INC | 0.2% | $7.5m | 150,000 | 0% | held | |
| 42 | TURNING POINT THERAPEUTICS I | 0.2% | $7.1m | 75,000 | 0% | held | |
| 43 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.2% | $6.9m | 550,000 | -49% | reduced |
| 44 | CLOV CLOVER HEALTH INVESTMENTS CO | Healthcare | 0.2% | $5.5m | 726,511 | – | new |
| 45 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.1% | $4.7m | 120,000 | 0% | held |
| 46 | FHTX FOGHORN THERAPEUTICS INC | Healthcare | 0.1% | $2.9m | 216,216 | 0% | held |
| 47 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.1% | $2.0m | 60,000 | – | new |
| 48 | CODIAK BIOSCIENCES INC | 0.0% | $1.2m | 76,688 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.